Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 490

1.

Mapping and modeling of a strain-specific epitope in the Norwalk virus capsid inner shell.

Parra GI, Sosnovtsev SV, Abente EJ, Sandoval-Jaime C, Bok K, Dolan MA, Green KY.

Virology. 2016 May;492:232-41. doi: 10.1016/j.virol.2016.02.019. Epub 2016 Mar 21.

2.

Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein.

Kim SH, Chen S, Jiang X, Green KY, Samal SK.

Virology. 2015 Oct;484:163-9. doi: 10.1016/j.virol.2015.06.003. Epub 2015 Jun 20.

3.

Application of salivary antibody immunoassays for the detection of incident infections with Norwalk virus in a group of volunteers.

Griffin SM, Converse RR, Leon JS, Wade TJ, Jiang X, Moe CL, Egorov AI.

J Immunol Methods. 2015 Sep;424:53-63. doi: 10.1016/j.jim.2015.05.001. Epub 2015 May 15.

4.

Mucosal and Cellular Immune Responses to Norwalk Virus.

Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, Atmar RL.

J Infect Dis. 2015 Aug 1;212(3):397-405. doi: 10.1093/infdis/jiv053. Epub 2015 Jan 29.

5.

Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity.

Czakó R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK.

Clin Vaccine Immunol. 2015 Feb;22(2):221-8. doi: 10.1128/CVI.00516-14. Epub 2014 Dec 24.

6.

In appreciation of Albert Z. Kapikian.

Green KY.

Clin Microbiol Infect. 2014 Aug;20(8):715. doi: 10.1111/1469-0691.12770. No abstract available.

7.

Two human challenge studies confirm high infectivity of Norwalk virus.

Kirby AE, Teunis PF, Moe CL.

J Infect Dis. 2015 Jan 1;211(1):166-7. doi: 10.1093/infdis/jiu385. Epub 2014 Aug 13. No abstract available.

PMID:
25121553
8.

Reply to Kirby et al.

Atmar RL, Opekun AR, Estes MK, Graham DY.

J Infect Dis. 2015 Jan 1;211(1):167. doi: 10.1093/infdis/jiu382. Epub 2014 Jul 10. No abstract available.

9.

Development of a Gaussia luciferase-based human norovirus protease reporter system: cell type-specific profile of Norwalk virus protease precursors and evaluation of inhibitors.

Qu L, Vongpunsawad S, Atmar RL, Prasad BV, Estes MK.

J Virol. 2014 Sep;88(18):10312-26. doi: 10.1128/JVI.01111-14. Epub 2014 Jul 9.

10.

The p4-p2' amino acids surrounding human norovirus polyprotein cleavage sites define the core sequence regulating self-processing order.

May J, Viswanathan P, Ng KK, Medvedev A, Korba B.

J Virol. 2014 Sep;88(18):10738-47. doi: 10.1128/JVI.01357-14. Epub 2014 Jul 2.

11.

The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.

Rocha-Pereira J, Nascimento MS, Ma Q, Hilgenfeld R, Neyts J, Jochmans D.

Antimicrob Agents Chemother. 2014 Aug;58(8):4675-81. doi: 10.1128/AAC.02546-13. Epub 2014 Jun 2.

12.

Disease course and viral shedding in experimental Norwalk virus and Snow Mountain virus infection.

Kirby AE, Shi J, Montes J, Lichtenstein M, Moe CL.

J Med Virol. 2014 Dec;86(12):2055-64. doi: 10.1002/jmv.23905. Epub 2014 Feb 14.

PMID:
24531909
13.

TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.

Hjelm BE, Kilbourne J, Herbst-Kralovetz MM.

Hum Vaccin Immunother. 2014;10(2):410-6. doi: 10.4161/hv.27147. Epub 2013 Nov 26.

14.

Determination of the 50% human infectious dose for Norwalk virus.

Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, Ramani S, Hill H, Ferreira J, Graham DY.

J Infect Dis. 2014 Apr 1;209(7):1016-22. doi: 10.1093/infdis/jit620. Epub 2013 Nov 18.

15.

Laboratory evidence of norwalk virus contamination on the hands of infected individuals.

Liu P, Escudero B, Jaykus LA, Montes J, Goulter RM, Lichtenstein M, Fernandez M, Lee JC, De Nardo E, Kirby A, Arbogast JW, Moe CL.

Appl Environ Microbiol. 2013 Dec;79(24):7875-81. doi: 10.1128/AEM.02576-13. Epub 2013 Oct 11.

16.

The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model.

Rocha-Pereira J, Jochmans D, Debing Y, Verbeken E, Nascimento MS, Neyts J.

J Virol. 2013 Nov;87(21):11798-805. doi: 10.1128/JVI.02064-13. Epub 2013 Aug 28.

17.

Expression and assembly of Norwalk virus-like particles in plants using a viral RNA silencing suppressor gene.

Souza AC, Vasques RM, Inoue-Nagata AK, Lacorte C, Maldaner FR, Noronha EF, Nagata T.

Appl Microbiol Biotechnol. 2013 Oct;97(20):9021-7. doi: 10.1007/s00253-013-5077-5. Epub 2013 Aug 8.

PMID:
23925532
18.

Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.

Chen Z, Sosnovtsev SV, Bok K, Parra GI, Makiya M, Agulto L, Green KY, Purcell RH.

J Virol. 2013 Sep;87(17):9547-57. doi: 10.1128/JVI.01376-13. Epub 2013 Jun 19.

19.

Epidemiology of norovirus gastroenteritis outbreaks in two primary schools in a city in eastern China.

Xu H, Lin Q, Chen C, Zhang J, Zhang H, Hao C.

Am J Infect Control. 2013 Oct;41(10):e107-9. doi: 10.1016/j.ajic.2013.01.040. Epub 2013 May 8.

PMID:
23663855
20.

Norwalk Virus Minor Capsid Protein VP2 Associates within the VP1 Shell Domain.

Vongpunsawad S, Venkataram Prasad BV, Estes MK.

J Virol. 2013 May;87(9):4818-25. doi: 10.1128/JVI.03508-12. Epub 2013 Feb 13.

Supplemental Content

Loading ...
Support Center